Nested Double Syringe for Platelet-Rich Plasma Concentration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating damaged tissue are inefficient in harnessing the regenerative powers of platelets and growth factors, leading to prolonged healing times due to inadequate concentration and delivery of autologous growth factors.
Innovation Solution
A double syringe apparatus with a centrifuge is used to separate and concentrate autologous plasma, achieving a platelet concentration factor of about 2, which is then injected into damaged tissue to enhance healing by promoting tissue regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional single syringe methods are used for plasma extraction, then the process is simple, but the platelet concentration and delivery efficiency are insufficient
Solution Approach 1:
The patent employs a nested syringe configuration where an inner syringe is positioned within an outer syringe. The inner syringe contains a smaller volume of plasma that has been concentrated with platelets, while the outer syringe contains a larger volume of less concentrated plasma. This nested arrangement allows for efficient delivery of the concentrated platelet portion directly to the injury site, thereby achieving high platelet concentration (improving_feature) without requiring an overly complex multi-device system (mitigating worsening_feature).
Solution Approach 2:
The patent segments the plasma into two distinct portions within the syringe system: a concentrated platelet-rich plasma in the inner syringe and a less concentrated plasma in the outer syringe. This segmentation allows the concentrated portion to be delivered separately and more efficiently to the target site, improving platelet delivery effectiveness while maintaining a relatively simple overall device structure.
2Productivity
If growth factor concentration is increased to enhance healing, then tissue regeneration improves, but the complexity of concentration and delivery systems increases
Solution Approach 1:
The patent performs preliminary concentration of platelets and growth factors in the inner syringe before delivery. By pre-concentrating the therapeutic factors in a small, controlled volume within the nested inner syringe, the system achieves rapid healing effect (improving_feature) while avoiding the need for complex real-time concentration mechanisms during delivery (mitigating worsening_feature).
Solution Approach 2:
The patent extracts and isolates the concentrated platelet-rich plasma into the inner syringe, separating it from the less concentrated plasma in the outer syringe. This extraction allows the high-concentration growth factor portion to be delivered independently and efficiently, achieving fast healing (improving_feature) without requiring the entire large-volume system to be complex (mitigating worsening_feature).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively accelerates tissue repair by delivering a high concentration of autologous growth factors directly to the damaged area, reducing healing time and enhancing tissue growth in orthopedic and neurological applications.
Implementation Method 1
subjecting the autologous blood to at least one centrifugation step to obtain an autologous plasma
Data Source
AI summary
A method of providing autologous conditioned plasma (ACP) for treatment of connective tissue injuries. The method comprises the steps of: (i) providing an apparatus comprising a centrifuge and a double syringe, the double syringe including an inner syringe body and an outer syringe body; (ii) drawing autologous blood into the outer syringe body; (iii) subjecting the autologous blood to at least one centrifugation step to obtain an autologous conditioned plasma (ACP); (iv) removing, with the inner syringe body, at least a portion of autologous conditioned plasma (ACP) from the outer syringe body; and (v) inject ACP for treatment of various cartilage or tendon damage or diseases.